Methods for Treating Cancer

JP2024511321A5Pending Publication Date: 2026-06-18GRADALIS INC
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
GRADALIS INC
Filing Date
2022-03-09
Publication Date
2026-06-18

AI Technical Summary

Technical Problem

Current cancer treatments lack precision in predicting responsiveness based on genetic mutations, particularly in cases of homologous recombination deficiency (HRD) due to disrupted DNA repair pathways, such as those caused by BRCA gene mutations, leading to genomic instability.

Method used

A method for predicting cancer responsiveness by determining the genotype of BRCA1 and/or BRCA2, along with other genes, and administering a treatment involving a nucleic acid sequence encoding granulocyte-macrophage colony stimulating factor (GM-CSF) and a specific sequence (SEQ ID NO:2) to identify patients responsive to cancer therapy.

Benefits of technology

The method effectively predicts cancer treatment responsiveness, enabling targeted therapy for patients with specific genotypes, enhancing treatment efficacy and potentially improving recurrence-free survival in cancers like ovarian cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000042_0000
    Figure 00000042_0000
  • Figure 00000042_0001
    Figure 00000042_0001
  • Figure 00000042_0002
    Figure 00000042_0002
Patent Text Reader

Abstract

Disclosed herein are methods for predicting cancer responsiveness in a cancer patient, and for treating cancer by genotyping one or more genes in the patient.
Need to check novelty before this filing date? Find Prior Art